In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Roche, Syrrx develop cancer, diabetes compounds

Executive Summary

Under terms of a three-year deal, F. Hoffmann-La Roche and Syrrx agreed to discover and develop cancer and Type II diabetes drug candidates that act on HDAC (histone deacetylase), a cancer target that regulates gene transcription, and 11-beta HSD-1, a metabolic target that reduces cortisol production. The programs are in the preclinical development stage.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register